UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 3.608

Sortiert nach

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

Diabetes, obesity & metabolism, 2017-01, Vol.19 (1), p.3-12

2017

Link zum Volltext

Verfügbarkeit prüfen

Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1133-1141

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial

Diabetes, obesity & metabolism, 2019-07, Vol.21 (7), p.1652-1660

2019

Link zum Volltext

Verfügbarkeit prüfen

The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences

Diabetes, obesity & metabolism, 2012-09, Vol.14 (9), p.780-788

Home, P. D.

2012

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2016-02, Vol.18 (2), p.159-168

2016

Link zum Volltext

Verfügbarkeit prüfen

Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial

Diabetes, obesity & metabolism, 2016-05, Vol.18 (5), p.500-507

2016

Link zum Volltext

Verfügbarkeit prüfen

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1032-1039

2017

Link zum Volltext

Verfügbarkeit prüfen

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1142-1149

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1148-1155

2018

Link zum Volltext

Verfügbarkeit prüfen

Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus

Diabetes, obesity & metabolism, 2019-03, Vol.21 (3), p.569-574

2019

Link zum Volltext

Verfügbarkeit prüfen

Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial

Diabetes, obesity & metabolism, 2016-11, Vol.18 (11), p.1055-1064

2016

Link zum Volltext

Verfügbarkeit prüfen

Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics

Diabetes, obesity & metabolism, 2023-09, Vol.25 (9), p.2495-2504

2023

Link zum Volltext

Verfügbarkeit prüfen

Comparison of faster‐acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed‐loop insulin delivery

Diabetes, obesity & metabolism, 2023-04, Vol.25 (4), p.1121-1124

2023

Link zum Volltext

Verfügbarkeit prüfen

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

Diabetes, obesity & metabolism, 2016-04, Vol.18 (4), p.366-374

2016

Link zum Volltext

Verfügbarkeit prüfen

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)

Diabetes, obesity & metabolism, 2015-08, Vol.17 (8), p.734-741

2015

Link zum Volltext

Verfügbarkeit prüfen

Hepatoselectivity and the evolution of insulin

Diabetes, obesity & metabolism, 2014-01, Vol.16 (1), p.1-8

2014

Link zum Volltext

Verfügbarkeit prüfen

A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review

Diabetes, obesity & metabolism, 2013-11, Vol.15 (11), p.978-986

2013

Link zum Volltext

Verfügbarkeit prüfen

U-100, pH-Neutral formulation of VIAject®: faster onset of action than insulin lispro in patients with type 1 diabetes

Diabetes, obesity & metabolism, 2012-03, Vol.14 (3), p.222-227

2012

Link zum Volltext

Verfügbarkeit prüfen

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1293-1297

2018

Link zum Volltext

Verfügbarkeit prüfen

Treat-to-target trials: uses, interpretation and review of concepts

Diabetes, obesity & metabolism, 2014-03, Vol.16 (3), p.193-205

Garber, A. J.

2014

Link zum Volltext

Verfügbarkeit prüfen

Insulin Centennial: Milestones influencing the development of insulin preparations since 1922

Diabetes, obesity & metabolism, 2022-01, Vol.24 (S1), p.27-42

2022

Link zum Volltext

Verfügbarkeit prüfen

IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity

Diabetes, obesity & metabolism, 2014-09, Vol.16 (S1), p.4-15

White, M. F.

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of basal‐first titration order in individuals with type 2 diabetes receiving short‐term intensive insulin therapy: An exploratory analysis of BEYOND V

Diabetes, obesity & metabolism, 2023-05, Vol.25 (5), p.1221-1228

2023

Link zum Volltext

Verfügbarkeit prüfen

Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes

Diabetes, obesity & metabolism, 2018-02, Vol.20 (2), p.419-426

2018

Link zum Volltext

Verfügbarkeit prüfen

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting

Diabetes, obesity & metabolism, 2018-10, Vol.20 (10), p.2371-2378

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 3.608

Suche als RSS-Feed

Aktive Filter

KollektionElectronic Journals Library

PublikationsformBuchkapitel

Zeitschrift / SerieDiabetes, Obesity & Metabolism

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1)
Mit Volltextzugriff
(3.608)

Publikationsform

Artikel
(3.608)

Sprache

Englisch
(3.608)
Japanisch
(371)
Norwegisch
(5)

Erscheinungsjahr

n.n

Thema

Endocrinology & Metabolism
(3.313)
Life Sciences & Biomedicine
(3.313)
Science & Technology
(3.313)
Diabetes
(2.626)
Diabetes Mellitus
(2.609)
Humans
(2.574)
Male
(1.527)
Insulin
(1.510)
Diabetes Mellitus, Type 2 - Drug Therapy
(1.477)
Female
(1.389)
Type 2 Diabetes
(1.295)
Middle Aged
(1.159)
Hypoglycemic Agents - Therapeutic Use
(880)
Glucose
(848)
Adult
(819)
Antidiabetics
(800)
Hypoglycemia
(761)
Hemoglobin
(737)
Aged
(719)
Diabetes Mellitus, Type 2 - Blood
(655)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(54)

Menü

Weitere Dienste

Einstellungen

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial

The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension

Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus

Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial

Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics

Comparison of faster‐acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed‐loop insulin delivery

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)

Hepatoselectivity and the evolution of insulin

A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review

U-100, pH-Neutral formulation of VIAject®: faster onset of action than insulin lispro in patients with type 1 diabetes

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin

Treat-to-target trials: uses, interpretation and review of concepts

Insulin Centennial: Milestones influencing the development of insulin preparations since 1922

IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity

Efficacy and safety of basal‐first titration order in individuals with type 2 diabetes receiving short‐term intensive insulin therapy: An exploratory analysis of BEYOND V

Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting

Aktive Filter

Suchergebnisse filtern